Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Abramson Cancer Center at Penn Medicine
Chengdu Zenitar Biomedical Technology Co., Ltd
Prescient Therapeutics, Ltd.
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
Columbia University
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
Columbia University
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Yale University
University College, London
BeiGene
4SC AG
Kyowa Kirin Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
University of Nebraska
University of Nebraska
Genmab
OncoSec Medical Incorporated
Stanford University
Genmab
Universitätsmedizin Mannheim
Karyopharm Therapeutics Inc
Thomas Jefferson University
miRagen Therapeutics, Inc.
Cyclacel Pharmaceuticals, Inc.
Rochester Skin Lymphoma Medical Group, PLLC
European Organisation for Research and Treatment of Cancer - EORTC
Eisai Inc.
Rochester General Hospital
Galderma R&D
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
miRagen Therapeutics, Inc.
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Peking Union Medical College Hospital
Fred Hutchinson Cancer Center
Yale University
Celgene
Roswell Park Cancer Institute
University of Chicago
City of Hope Medical Center